Aurora Spine reported six month company results for 2014 and discussed business growth for the future.
Here are five key takeaways from the company's report:
1. Hospital approvals for the company's FDA-approved ZIP ULTRA and sterile-packed titanium plasma spray coated Ti-Nano MIS interbody spinal fusion system increased to 76 hospitals. Further expansion is a key goal for the company throughout the rest of the year.
2. The company received initial Ti-Nano implants from their manufacturers and began supplying it to their distributors with the products for the third quarter.
3. Aurora Spine added a new regional vice president of sales for the eastern United States, expanding overall sales efforts in the country.
4. There were distributors in the United States, Australia, Germany, Israel, Spain and Poland added during the first six months of 2014.
5. In the third quarter, the company plans to introduce the ZIP Graft Bone Dowel. The company continues to focus on new product development in addition to their sales expansion strategy.
"Aurora Spine is well positioned to capitalize on the market's demand for advanced solutions to spinal care and we look forward to the sustained growth of our business during 2014 and 2015," according to a company statement.